Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Adefovir Dipivoxil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 3/20 | 0.93 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.93 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.93 |
| ▸ | POLA1 | P09884 | 1/20 | 0.93 |
| ▸ | POLG | P54098 | 1/20 | 0.93 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.58 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.45 |
| ▸ | NT5E | P21589 | 1/20 | 0.44 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.43 |
| ▸ | NSD3 | Q9BZ95 | 2/20 | 0.42 |
| ▸ | NSD2 | O96028 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adefovir Dipivoxil SCHEMBL5845498 | 0.96 | FAP (1.00) | FAPSLC22A6ABCB11POLA1POLG | |
| Adefovir Dipivoxil SCHEMBL29372789 | 0.96 | FAP (1.00) | FAPSLC22A6ABCB11POLA1POLG | |
| Adefovir Dipivoxil SCHEMBL29729 | 0.96 | FAP (1.00) | FAPSLC22A6ABCB11POLA1POLG | |
| Adefovir Dipivoxil SCHEMBL3646944 | 0.95 | FAP (0.98) | FAPSLC22A6ABCB11POLA1POLG | |
| Adefovir Dipivoxil SCHEMBL3719079 | 0.95 | FAP (0.98) | FAPSLC22A6ABCB11POLA1POLG | |
| Adefovir Dipivoxil SCHEMBL3745803 | 0.93 | FAP (0.93) | FAPSLC22A6ABCB11POLA1POLG | |
| SCHEMBL12391572 | 0.93 | FAP (0.93) | FAPSLC22A6ABCB11POLA1POLG | |
| Adefovir Dipivoxil SCHEMBL2787331 | 0.91 | FAP (0.88) | FAPSLC22A6ABCB11POLA1POLG | |
| SCHEMBL13239804 | 0.90 | FAP (0.87) | FAPSLC22A6ABCB11POLA1POLG | |
| SCHEMBL12391569 | 0.88 | SLC22A6 (0.84) | FAPSLC22A6ABCB11POLA1POLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120238753-A1 | PROCESS FOR THE PREPARATION OF ADEFOVIR DIPIVOXIL | MYLAN LABORATORIES LIMITED (IN) | 2012-09-20 | — | — | US | claimed |
| WO-2012032541-A1 | \"ADEFOVIR DIPIVOXIL PSEUDOPOLYMORPH\ | MATRIX LABORATORIES LTD (IN) | 2012-03-15 | — | — | WO | claimed |
| US-20120238753-A1 | PROCESS FOR THE PREPARATION OF ADEFOVIR DIPIVOXIL | MYLAN LABORATORIES LIMITED (IN) | 2012-09-20 | — | — | US | disclosed |
| WO-2012032541-A1 | \"ADEFOVIR DIPIVOXIL PSEUDOPOLYMORPH\ | MATRIX LABORATORIES LTD (IN) | 2012-03-15 | — | — | WO | disclosed |
| WO-2012032541-A1 | \"ADEFOVIR DIPIVOXIL PSEUDOPOLYMORPH\ | MATRIX LABORATORIES LTD (IN) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238753-A1 | PROCESS FOR THE PREPARATION OF ADEFOVIR DIPIVOXIL | DCTD, PEPD, MTAP | FAP 202/4885SLC22A6 2825/4885ABCB11 1852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.